Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001209191-20-060793
Filing Date
2020-11-30
Accepted
2020-11-30 18:14:03
Documents
1
Period of Report
2019-01-02

Document Format Files

Seq Description Document Type Size
1 FORM 4/A SUBMISSION doc4a.html 4/A  
1 FORM 4/A SUBMISSION doc4a.xml 4/A 26336
  Complete submission text file 0001209191-20-060793.txt   27757
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BLVD., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Ho Carole (Reporting) CIK: 0001724605 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-38311 | Film No.: 201359287